5-硝基-6-氯烟酸 | 7477-10-3

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-硝基-6-氯烟酸
• 中文别名: 6-氯-5-硝基烟酸
• 英文名称: 6-chloro-5-nitronicotinic acid
• 英文别名: 6-chloro-5-nitropyridine-3-carboxylic acid
• CAS: 7477-10-3
• 化学式: C₆H₃ClN₂O₄
• mdl: MFCD09027297
• 分子量: 202.554
• InChiKey: HCRHNMXCDNACMH-UHFFFAOYSA-N

物化性质

• 沸点：
  401.3±45.0 °C(Predicted)
• 密度：
  1.702

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Chloro-5-Nitronicotinic Acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 202,55 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
6-Chloro-5-Nitronicotinic Acid
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
6-Chloro-5-Nitronicotinic Acid
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  5-硝基-6-氯烟酸 在 氯化亚砜 、 氨 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 6.5h， 生成 6-(Aziridin-1-yl)-5-nitropyridine-3-carboxamide
  参考文献：
  名称：

  THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF

  摘要：

  公开号：

  EP2366691B1
• 作为产物：
  描述：

  2-羟基-3-硝基吡啶-5-羧酸 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以20 g的产率得到5-硝基-6-氯烟酸
  参考文献：
  名称：

  酰胺类化合物及其制备方法和应用

  摘要：

  本发明涉及酰胺类化合物及其制备方法和应用，该酰胺类化合物具有式(I)所示结构：上述酰胺类化合物能够诱导动物体内内源性干扰素的产生，具有开发为抗病毒药物的潜能。

  公开号：

  CN113429426A
• 作为试剂：
  描述：

  2-羟基-3-硝基吡啶-5-羧酸 、 五氯化磷 、 三氯氧磷 、 氨 、 四氢呋喃 、 水 在 氮 、 resultant solution 、 5-硝基-6-氯烟酸 、 acid chloride 、 四氢呋喃 、 二氯甲烷 、 Sodium sulfate-III 作用下， 反应 4.0h， 以to afford the title compound (0.72 g, 3.57 mmol, 49%) as a yellow solid的产率得到6-chloro-5-nitronicotinamide
  参考文献：
  名称：

  5-arylindole derivatives

  摘要：

  式(I)的化合物，其中R.sub.1是(a)，(b)，(c)或(d)；n为0，1或2；A，B，C和D各自独立地为氮或碳；R.sub.2，R.sub.3，R.sub.4和R.sub.5各自独立地为氢，C.sub.1至C.sub.6烷基，芳基，C.sub.1至C.sub.3烷基芳基，卤素（例如氟，氯，溴或碘），氰基，硝基，--(CH.sub.2).sub.m NR.sub.14 R.sub.15，--(CH.sub.2).sub.m OR.sub.9，--SR.sub.9，--SO.sub.2 NR.sub.14 R.sub.15，--(CH.sub.2).sub.m NR.sub.14 SO.sub.2 R.sub.15，--(CH.sub.2).sub.m NR.sub.14 CO.sub.2 R.sub.9，--(CH.sub.2).sub.m NR.sub.14 COR.sub.9，--(CH.sub.2).sub.m NR.sub.14 CONHR.sub.9，--CONR.sub.14 R.sub.15，或--CO.sub.2 R.sub.9；R.sub.2和R.sub.3，R.sub.3和R.sub.4，或R.sub.4和R.sub.5可以共同形成五到七元的烷基环，六元的芳基环，具有1个N、O或S杂原子的五到七元的杂烷基环或具有1或2个N、O或S杂原子的五到六元的杂芳基环及其药学上可接受的盐。这些化合物对治疗偏头痛和其他疾病有用。这些化合物是有用的心理治疗药物，是有效的5-羟色胺（5-HT.sub.1）激动剂和苯二氮平激动剂和拮抗剂，可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、集群头痛、偏头痛、疼痛和慢性阵发性半侧头痛以及与缺乏5-羟色胺能神经递质有关的其他疾病。这些化合物还可用作中枢作用降压剂和扩血管剂。

  公开号：

  US05886008A1

文献信息

• [EN] 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES<br/>[FR] DÉRIVÉS DE 9-AMINOACRIDINE, LEUR PRÉPARATION ET LEURS UTILISATIONS
  申请人：UNIV ARIEL RES & DEV CO LTD

  公开号：WO2011051950A1

  公开（公告）日：2011-05-05

  N-substituted 9-aminoacridine and bis-acridino derivatives containing electron- withdrawing groups (EWG) or electron-donating groups (EDG), including amino acid residues, and one-pot methods for their synthesis are disclosed. The derivatives are potential candidates for cancer treatment.

  含有取代基的9-氨基吖啶和含有电子吸引基团（EWG）或电子供给基团（EDG）的双吖啶衍生物，包括氨基酸残基，以及它们的合成的一锅法被披露。这些衍生物是潜在的癌症治疗候选物。
• Compounds useful for treating hepatitis C virus
  申请人：——

  公开号：US20030134853A1

  公开（公告）日：2003-07-17

  A series of compounds of Formula I are disclosed which are useful in treating viral hepatitus C. 1

  披露了一系列的I公式化合物，这些化合物在治疗丙型病毒性肝炎方面是有用的。
• [EN] AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF<br/>[FR] COMPOSÉS AMIDES, COMPOSITIONS ET APPLICATIONS DE CEUX-CI
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2013042139A1

  公开（公告）日：2013-03-28

  The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Fatty Acid Amide Hydrolase (FAAH), such as pain including acute and post operative pain, chronic pain, cancer pain, cancer chemotherapy induced pain, neuropathic pain, nociceptive pain, inflammatory pain, back pain, pain due to disease of various origin such as: diabetic neuropathy, neurotropic viral disease including human immunodeficient virus (HIV), herpes zoster such as post herpetic neuralgia; polyneuropathy, neurotoxicity, mechanical nerve injury, carpal tunnel syndrome, immunologic mechanisms like multiple sclerosis; sleep disorders, anxiety and depression disorders, inflammatory disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, hypertension or other disorders. The disclosure also relates to the process of preparation of the amide compounds. Formula (1). The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

  本公开涉及替代酰胺化合物，这些化合物是脂肪酸酰胺水解酶（FAAH）的抑制剂，包括它们的立体异构体、互变异构体、前药、多型体、溶剂合物、药用盐以及含有它们的药物组合物。这些化合物在治疗、预防、预防、管理或辅助治疗与脂肪酸酰胺水解酶（FAAH）抑制相关的所有医疗状况中非常有用，例如疼痛，包括急性和术后疼痛，慢性疼痛，癌症疼痛，癌症化疗引起的疼痛，神经痛，伤害性疼痛，炎症性疼痛，背部疼痛，疾病引起的疼痛，如糖尿病性神经病变，神经病毒性疾病，包括人类免疫缺陷病毒（HIV），带状疱疹，如带状疱疹后神经痛；多发性神经病，神经毒性，机械神经损伤，腕管综合症，类似多发性硬化的免疫机制；睡眠障碍，焦虑和抑郁症，炎症性疾病，体重和进食障碍，帕金森病，成瘾，痉挛，高血压或其他疾病。该公开还涉及酰胺化合物的制备过程。公式（1）。本公开还涉及制备这类化合物的方法，以及含有它们的药物组合物。
• [EN] BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES<br/>[FR] BENZIMIDAZOLE ET AZA-BENZIMIDAZOLE CARBOXAMIDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010051245A1

  公开（公告）日：2010-05-06

  This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.

  这项发明提供了化合物I的公式，这些化合物是PAFR拮抗剂：I及其药用盐。这些化合物可用于治疗PAF介导的疾病，并可用于治疗动脉粥样硬化并预防或减少动脉粥样硬化疾病事件的风险的方法。这些化合物还可用于治疗或缓解疼痛，例如炎症性疼痛和/或伤害性疼痛，并用于治疗或缓解自身免疫和/或炎症性疾病等其他疾病。
• 磺酰胺基烟酸衍生物、酰胺基烟酸衍生物及其制备方法和应用
  申请人：苏州大学

  公开号：CN113248427B

  公开（公告）日：2023-05-02

  本发明提供了烟酸磺酰胺基衍生物和烟酸酰胺基衍生物，分别具有式(Ⅰ)和式(Ⅳ)所示结构。实验结果表明，本发明提供的磺酰胺基烟酸衍生物和酰胺基烟酸衍生物具有较好的治疗动脉粥样硬化活性，可以作为制备相关动脉粥样硬化治疗药物。